METASTATIC CANCER

This phase 2 trial tests whether adding a second DNA vaccine to a standard immunotherapy (pembrolizumab) can improve outcomes for men with castration-resistant metastatic prostate cancer. About 60 participants will receive either one or two DNA vaccines along with pembrolizumab f…

This early-phase trial tests an experimental drug called IPH5301, which targets a protein called CD73 on cancer cells. The study involves 27 people with advanced solid tumors, including breast, lung, and pancreatic cancers. In the first part, IPH5301 is given alone to find a safe…

This study tests whether adding the drug azeliragon to targeted radiation therapy can safely shrink brain tumors and keep them under control longer. It involves 46 adults with cancer that has spread to the brain. The goal is to improve tumor control without causing serious side e…

This early-phase trial tests an investigational drug called RP-6306 alongside standard chemotherapy (carboplatin and paclitaxel) in 6 women with recurrent ovarian or uterine cancer that has a specific genetic change (TP53 mutation). The main goal is to find a safe dose and check …

This phase 2 trial tests a drug called lorigerlimab (MGD019) in 47 people with advanced cervical cancer that has spread or come back. The goal is to see if the drug can help control the cancer and improve survival. Participants receive the drug through an IV. The study is current…

This phase II trial tests whether delivering chemotherapy directly into the liver (hepatic arterial infusion) along with standard IV chemo can shrink inoperable liver tumors from colorectal cancer enough to allow surgical removal. The study involves 64 participants whose cancer h…

This study tests the drug niraparib in 20 people whose cancer has spread to the brain or spinal cord. The goal is to see if the drug can shrink or control these tumors. Participants must have mild or no symptoms from their brain metastases and not need increasing steroids or seiz…

This early-stage trial tests a new drug, ALTA2618, in about 110 adults whose advanced solid tumors (like breast or endometrial cancer) have a specific genetic change called AKT1 E17K. The main goals are to check the drug's safety and find the right dose. Participants must have tr…

This early-phase study tests whether a new drug called AZD1390 is safe when given together with a precise type of radiation therapy (SBRT) for people whose solid tumors have spread to other parts of the body. The study involves 54 adults with metastatic cancer. The main goal is t…

This early-phase trial is testing a new drug called NTX-1088, which targets a protein on cancer cells, either alone or combined with the immunotherapy pembrolizumab. The study involves 90 people with advanced solid tumors that have spread or cannot be removed. The main goals are …

This early-stage study tests a new drug that delivers radiation directly to cancer cells that make a protein called CEA. It is for people with advanced colorectal or other CEA-positive cancers that have spread. The main goals are to find the safest dose and understand side effect…

This phase 2 trial tests whether adding ramucirumab to the standard drug osimertinib helps people with advanced EGFR-mutant lung cancer live longer without their disease worsening. About 160 patients will receive either the combination or osimertinib alone. The study aims to see …

This phase 2 study compares two dosing schedules of the targeted drug adagrasib (Krazati) in 200 adults with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. Participants have already tried chemotherapy and immunotherapy. The goal is to see if a lower d…

This early study tests whether adding three cholesterol-lowering drugs (atorvastatin, ezetimibe, and evolocumab) to standard chemotherapy can slow or stop pancreatic cancer growth. Cancer cells need lots of cholesterol to grow, and this approach aims to starve them. The trial inc…

This early-phase trial tests an HPV vaccine series in healthy relatives of patients with advanced HPV-related cancer. The goal is to generate HPV-specific white blood cells that can be collected and used in a bone marrow transplant or donor lymphocyte infusion for the patient. Th…

This study tests whether giving a precise, high-dose radiation treatment (SBRT) to bone tumors before surgery is safe and can prevent the cancer from returning. About 39 adults with cancer that has spread to their bones and who need surgery to stabilize a fracture risk will recei…

This phase 2 trial tests a combination of three drugs—pemetrexed, etrumadenant, and zimberelimab—in 10 people with advanced bladder cancer that has a specific genetic change (MTAP deficiency) and has already been treated with immunotherapy. The goal is to see if the combo is safe…

This study looks at whether giving precise, high-dose radiation to a small number of growing cancer spots can help people with metastatic non-small cell lung cancer stay stable longer. About 90 adults whose cancer has started to grow in just a few places while on standard treatme…

This phase 2 trial tests whether avelumab, an immunotherapy drug, can shrink tumors in 25 people with advanced penile cancer who cannot take platinum chemotherapy or whose cancer worsened after it. Avelumab works by blocking a protein that helps tumors hide from the immune system…

This study tests the safety of combining the drug RP-3500 with radiation therapy for people whose cancer has spread and who have a specific gene change (ATM mutation). About 49 adults with advanced solid tumors will receive the combination to find the safest dose and see if it he…

This study tests whether a precise type of radiation called SBRT can restore the effectiveness of immunotherapy drugs in people whose metastatic cancer has started to progress. About 69 adults with melanoma, lung, bladder, kidney, or head/neck cancers will receive radiation to up…

This study tests a drug called adagrasib (MRTX849) in people with advanced solid tumors that have a specific genetic mutation called KRAS G12C. The goal is to see if the drug is safe, how the body processes it, and whether it can shrink tumors. About 731 participants with various…

This study tests whether adding two targeted drugs (avutometinib and defactinib) to standard chemotherapy can help people with metastatic pancreatic cancer that hasn't been treated yet. About 40 adults with this cancer will receive the combination. The goal is to find the safest …

This study tests a special PET scan that uses a radioactive antibody (64Cu-M5A) to find cancers that produce a protein called CEA. The goal is to see if this scan can detect tumors that standard methods might miss. About 20 adults with CEA-positive cancers (such as breast, colon,…

This study looks at whether an 8-week digital program called COBRA, which includes balance and resistance exercises, is safe and practical for older adults with cancer. The program is delivered via an iPad with video calls. Researchers will track how many participants stick with …

This study tests whether a newer, more precise type of single-dose radiation can provide longer-lasting relief from pain and other symptoms caused by cancer that has spread. About 100 people with metastatic cancer who are already recommended for standard single-dose radiation wil…

This study tests a communication program for people with advanced cancer and their caregivers. The goal is to help them manage difficult emotions and talk about the patient's illness and treatment wishes. About 45 participants will take part, and the program is tailored for Latin…

This study looks at whether having a radiation oncologist involved early in care, alongside standard treatment, can improve quality of life for people with metastatic cancer. About 156 adults with cancer that has spread and is not curable will be randomly assigned to either stand…

This study compares two ways of giving high-dose radiation to people whose cancer has spread to bones, spine, soft tissue, or lymph nodes. One schedule gives the radiation in one day, the other over three days. The goal is to see which schedule better controls tumor growth and ha…

This study planned to test whether adding low-dose radiation to standard high-dose radiation could trigger an 'abscopal effect' – where untreated tumors also shrink. It was designed for adults with metastatic solid tumors. However, the study was withdrawn before any patients were…

This study collects white blood cells and tumor cells from cancer patients, and white blood cells from healthy volunteers, to help researchers grow anti-cancer cells in the lab. The goal is to create experimental cell therapies for future use. Up to 7,000 participants will provid…

This study aimed to review past cases of a treatment called radioembolization (using tiny radiation beads) for liver tumors, including a rare type of bile duct cancer. The goal was to understand how well it works and what risks it carries. However, the study was withdrawn before …

This research study looks at how certain cancers (head and neck, esophagus, and anal canal) change at the genetic and immune level when patients receive chemotherapy or immunotherapy. About 39 people with advanced cancer will provide blood samples and tumor tissue over time. The …

This study looks at whether analyzing the genes of a tumor (from a tissue sample or a blood test) can help doctors pick a more effective treatment for people with advanced solid cancers that have stopped responding to standard therapies. About 235 participants will have their tum…

This study collects tumor and blood samples from 180 people with metastatic cancer who are receiving or have received the drug T-DXd. Researchers will analyze these samples to find genetic markers that predict whether the drug will work well. The goal is to improve treatment deci…

This pilot study is looking for biomarkers in the blood that might predict which cancer patients will develop immune-related side effects from immune checkpoint inhibitors. Researchers will compare blood samples from 69 patients with metastatic cancer before and during treatment.…